China SXT Pharmaceuticals, Inc. entered into an amendment to its Securities Purchase Agreement with institutional investors on August 27, 2026. The company previously executed a 1-for-80 share consolidation effective August 10, 2026, which adjusted the floor price for pre-paid purchases from $0.20 to $16.00 per share. The amendment reduced this floor price back to $0.20 per share while maintaining an aggregate principal amount of up to $31,500,000. This transaction involves the issuance and sale of Class A ordinary shares. China SXT Pharmaceuticals operates in the pharmaceutical industry, focusing on the research, development, and manufacturing of drugs.

China SXT Pharmaceuticals, Inc. entered into a securities purchase agreement with an institutional investor for up to $30,000,000 in pre-paid purchases of Class A ordinary shares. The initial purchase of $3,150,000 is expected to be closed on July 6, 2026, with a 5% original issue discount and 7% annual interest. Subsequent purchases between $250,000 and $3,000,000 are permitted within a two-year commitment period. The company is a pharmaceutical company focused on developing and commercializing anti-infective drugs.